» ГЛАВНАЯ > К содержанию номера
» Все публикации автора
Журнал научных публикаций
«Наука через призму времени»
Декабрь, 2025 / Международный научный журнал
«Наука через призму времени» №12 (105) 2025
Автор: Agayeva D., Teacher
Рубрика: Педагогические науки
Название статьи: Evaluating the efficacy of telemedicine and artificial intelligence in personalized cancer treatment
Дата публикации: 12.12.2025
скачать
EVALUATING
THE EFFICACY OF TELEMEDICINE AND ARTIFICIAL INTELLIGENCE IN PERSONALIZED CANCER
TREATMENT
Agayeva D.
Teacher,
Meredov A.
Student
The
International University of Industrialists and Entrepreneurs
Ashgabat,
Turkmenistan
Abstract. The shift toward personalized
cancer treatment necessitates innovative technological solutions to optimize
patient care, streamline clinical workflows, and enhance treatment efficacy.
This study evaluates the integration and effectiveness of telemedicine and
Artificial Intelligence (AI) in delivering individualized oncology protocols.
Telemedicine platforms facilitate remote patient monitoring, virtual consultations,
and symptom management, significantly improving access to specialized care,
particularly in rural or underserved areas. AI plays a crucial role by
leveraging sophisticated algorithms for data analysis, including genomic
sequencing, radiological imaging, and electronic health records. This allows
for the precise identification of therapeutic targets, prediction of treatment
response, and optimization of dosing schedules based on individual patient
profiles, moving beyond traditional one-size-fits-all approaches. The research
specifically assesses the impact of this dual integration on key metrics:
patient adherence, treatment toxicity reduction, and overall survival rates.
Keywords: telemedicine, artificial
intelligence (AI), personalized cancer treatment, oncology, patient care,
remote monitoring, genomic sequencing, treatment efficacy, data privacy,
personalized medicine.
The
landscape of modern oncology is undergoing a rapid transformation, moving
decisively away from standardized protocols toward highly individualized
treatment strategies. This paradigm shift, known as personalized cancer
treatment, necessitates tools capable of handling vast datasets and
facilitating continuous, adaptive patient management. This evolving environment
demands innovative technological integration to maximize therapeutic outcomes
while minimizing patient burden.
Personalized
medicine in cancer relies heavily on understanding the unique molecular
characteristics of an individual's tumor, including genomic mutations, transcriptomic
profiles, and environmental factors. The goal is to select targeted therapies,
optimal dosages, and intervention schedules that are specifically tailored to
the patient, rather than the average population response. Achieving this level
of precision requires sophisticated computational power and seamless data
exchange.
Telemedicine
represents the vital communication and monitoring layer of this personalized
approach. It encompasses a range of technologies allowing remote healthcare
delivery, including virtual consultations, digital patient portals, and
wearable devices for continuous vital sign tracking. These capabilities
dramatically reduce the necessity for frequent in-person clinic visits,
enhancing convenience and reducing costs for the patient.
The
efficacy of telemedicine is particularly evident in managing chronic conditions
like cancer, where continuous symptom monitoring and timely intervention are
critical. Remote platforms enable rapid reporting of adverse effects and
treatment toxicities, allowing clinicians to adjust medications or supportive
care immediately. This real-time adaptive management is a cornerstone of
personalized care and contributes directly to improved quality of life.
Artificial
Intelligence (AI), conversely, provides the analytical engine required to
interpret the complexity of individualized cancer data. AI utilizes machine
learning algorithms to process massive volumes of multi-modal data, including
genomic sequencing reports, pathology slides, radiological images, and
structured clinical notes. This processing power is beyond human capacity and
is essential for effective personalization.
One of the
primary applications of AI in personalized oncology is the accurate prediction
of therapeutic response. By training models on patient cohorts with similar
molecular profiles and known outcomes, AI can forecast which patients are most
likely to benefit from a specific drug or combination therapy. This predictive
capability minimizes unnecessary treatment, thereby reducing toxicity and
healthcare expenditures.
Furthermore,
AI plays a crucial role in optimizing radiation therapy planning and surgical
strategies. Advanced deep learning models can rapidly delineate tumor
boundaries and critical organs-at-risk from medical images with superior
consistency and speed compared to manual human processes. This precision leads
to more effective tumor targeting and significantly lower collateral damage to
healthy tissues.
The
synergy between telemedicine and AI creates a closed-loop system for continuous
learning and adaptation. Data gathered remotely via telemedicine devices (e.g.,
activity levels, sleep patterns, self-reported symptoms) feeds back into AI
models. The AI then refines its predictive models or suggests necessary
treatment modifications, which are then implemented via the telemedicine
interface.
Despite
the immense potential, the deployment of this integrated system faces
significant challenges, particularly concerning data standardization and
interoperability. Cancer data often reside in disparate systems, utilizing
different formats and terminologies, which creates bottlenecks for AI model
training and real-time clinical application. Establishing universal data
standards is a critical prerequisite for success.
Another
substantial challenge is the ethical and regulatory landscape surrounding the
use of patient data and autonomous AI decision--making tools. Stringent privacy
regulations, such as HIPAA and GDPR, must be strictly adhered to while ensuring
that AI algorithms are transparent, explainable, and free from inherent biases
that could compromise equitable treatment across diverse patient populations.
The
economic feasibility of implementing these high-tech solutions in diverse
healthcare settings also warrants critical evaluation. While AI and
telemedicine promise long-term cost savings through efficiency and better
outcomes, the initial capital investment in infrastructure, software, and
training can be prohibitive for smaller institutions or developing healthcare
systems.
Evaluating
the true efficacy of this technological blend requires robust clinical trials
focused on specific, measurable metrics. Traditional survival endpoints must be
complemented by patient-reported outcomes (PROs), quality of life assessments,
and adherence rates, all of which are directly influenced by the convenience
and continuous support offered by telemedicine.
A key
advantage of remote monitoring is its potential to improve patient adherence to
complex oral chemotherapy regimens. Telemedicine applications can provide
timely reminders, educational content, and direct communication channels,
mitigating confusion and helping patients stay on track with their personalized
treatment plan, which is vital for curative intent.
The impact
on health equity is also a pivotal area of investigation. Telemedicine can
bridge geographical barriers, allowing patients in rural areas access to highly
specialized oncology expertise housed in centralized urban centers. However,
this relies on reliable internet access and digital literacy, posing new
challenges related to the "digital divide."
The
findings of this evaluation will inform policy decisions, guide technology
investment in healthcare infrastructure, and ultimately help establish best practices
for the sustainable implementation of integrated AI and telemedicine solutions
in global cancer care.
Reference:
- Esteva, A., Robicquet, A., Ramsundar, B., Kuleshov, V., DePristo, M., Chou, K., ... & Thrun, S. (2017). A guide to deep learning in healthcare. Nature Medicine, 23(11), 1279–1288.
- Kvedar, J., Colman, A., & Coye, M. J. (2019). The new consumer-driven digital health. Health Affairs, 38(11), 1836–1842.
- Kontos, E., Blake, K. D., Chou, W. Y. S., & Prestin, A. (2019). The relationship between eHealth literacy and the use of the Internet for health information: a systematic review. Journal of Medical Internet Research, 21(12), e14569.
- Rajpurkar, P., Chen, E., Banerjee, O., & Topol, E. J. (2022). AI in health and medicine. Nature Medicine, 28(1), 31–38.
Комментарии:
